Drug approval is often a necessarily long process, but for cannabis there are actually the extra hurdles of lawful roadblocks, and also the problem in getting patent protections for normal compounds.Synthetic cannabinoids (SCs) are a category of compounds comparable in pharmacological and physiological outcomes to tetrahydrocannabinol (THC), the mo